Top of this page
Skip navigation, go straight to the content

Investors Overview

At UCB,
we aspire to be the patient-preferred biotech leader. 

To achieve this goal, UCB has become an innovation-driven global biopharmaceutical company creating value for patients, the company, its shareholders and society in general.

Our work has an impact on the lives of many people. Every UCB employee is committed to follow the strict regulatory standards for research, development, manufacturing and distribution of our products to ensure we meet all safety, quality, regulatory, legal and environmental requirements.

In an ever-changing and more complex environment, UCB’s patient value strategy is the best route to achieve this ambition and long-term success. 

Agreement to acquire
Ra Pharma

Business general picture

 

IR events

DateEvent details
20 November
2019
Jefferies 2019 Healthcare Conference, London1/1 meetings
12 December
2019
Roadshow in BrusselsIf you are interested in meeting UCB, please contact KBC.
13 December
2019
Kepler Cheuvreux Conference, Brussels1/1 meetings

2018 integrated report

image description
 

2019 HY results

image description

Upcoming report

DateEvent details
20 February
2020
2019 full year results 07.00 Press release
14.00 Conference call /webcast
Exact timing to be confirmed closer to the time
 
 

Outlook 2019 confirmed

The acquisition of Ra Pharma will not impact UCB’s 2019 financial guidance. The acquisition would be dilutive to UCB’s mid-term earnings level due to additional planned R&D investments. As a result, the mid-term target of UCB reaching a REBITDA ratio (to revenue) of 31% would move to 2022 from 2021 as previously guided.

2019 revenue reporting to reach approximately

€ 4.6-4.7 billion 

Recurring EBITDA [Operating profit adjusted for amortisation, depreciation, impairment charges, restructuring expenses and other exceptional income and expenses.] in the range of

27-29% of revenue 

Core earnings per share are therefore expected in the range of

€ 4.40-4.80

based on an average of
188 million shares outstanding

Contact UCB IR team

investor-relations@ucb.com or a specific team member:

 

UCB IR App

 

UCB IR app available on Apple Store


UCB IR app available on Google Play